Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Karnataka: Shilpa Pharma Lifesciences Limited, a 100 percent subsidiary of Shilpa Medicare Limited has received certificate ...

IST, the barometer index, the S&P BSE Sensex rose 154.28 points or 0.20% to 76,559.27. The Nifty 50 index added 64.95 points or 0.28% to 23,220.30.

The FDA recalled 23,304 bottles of Dapsone Gel 7.5% due to crystal formation, potentially reducing effectiveness and safety.

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

The FDA has recalled 23,304 bottles of Dapsone Gel 7.5%, an acne treatment, due to crystallization that can impact dosage and ...

Housing & Urban Development Corp., Paras Defence and Space Technologies Ltd. and Waaree Energies Ltd. are some stocks that ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Jio Financial Services and BlackRock further subscribed to Rs 5.85 crore shares of JV Jio BlackRock Asset Management for Rs ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...